The field of nanomedicines has expanded
significantly in recent years in the breadth of compounds under development as
well as in the types
of technology that are being applied to
generate nanomedicines. The pathway to licensure of new
nanomedicines is sufficiently well
defined by existing regulations and guidance.
The future of nanomedicines requires collaboration between industry and regulatory
agencies to ensure that safe and effective nanomedicines emerge from this
field.
Nanotechnology - Technology for every facet of life
Tuesday, July 29, 2014
Tuesday, July 22, 2014
Polysilsesquioxane Nanoparticles for Triggered Release of Cisplatin and Effective Cancer Chemoradiotherapy
An innovative strategy is to utilize nanoparticle (NP)chemotherapeutics in chemoradiation. Since the most commonly utilized chemotherapeutic with radiotherapy is cisplatin, the development of a NP cisplatin for chemoradiotherapy has the highest potential impact on this treatment. Here, we report the development of a NP comprised of polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin prodrug (Cisplatin-PSQ) and its utilization in chemoradiotherapy using non-small cell lung cancer as a disease model. Cisplatin-PSQ NP has an exceptionally high loading of cisplatin. Cisplatin-PSQ NPs were evaluated in chemoradiotherapy in vitro and in vivo. They demonstrated significantly higher therapeutic efficacy when compared to cisplatin. These results suggest that the Cisplatin-PSQ NP holds potential for clinical translation in chemoradiotherapy.
Friday, July 4, 2014
Thursday, July 3, 2014
Friday, February 21, 2014
Tuesday, February 11, 2014
Researchers create promising compound for cancer treatment
A promising compound for cancer treatment has been syntesised in a laboratory by an RMIT University researcher during his PhD research.
Dr Dan Balan, from the School of Applied Sciences at RMIT, said 15-aza-Salicylihalamide A analogue had demonstrated potent activity against several leukaemia cell lines.
"Salicylihalamide A is an interesting natural marine product that has been isolated from a marine sponge of the genus Haliclona, collected from waters around Rottnest Island, 18 km off the coast of southern Western Australia," Dr Balan said.
Salicylihalamide A is cytotoxic - or a toxin which is known to destroy cells and which also provides a defence for the sea sponge.
"My goal was to synthesise the chemical in the laboratory in the form of a single aza-salicylihalamide A analogue molecule," he said.
The aza-salicylihalamide A analogue molecules were then exposed to NCI-60 leukaemia cell lines, and exhibited antiproliferating effects on the group of cells at highly diluted, or 'sub-molar', concentrations.
"15-aza-Salicylihalamide A Analogue has proven to be very active against various types of cancer, but it was clearly most active against HL-60, which is acute promyelocytic leukaemia," he said.
Other findings revealed it to be an inhibitor of vacuolar ATPase and proton pumps, frequently found in metastatic cancer cells - which are cancer cells that have migrated through the bloodstream from more advanced tumours.
"The molecule was synthesised in a short molecular sequence that could be easily produced in very large volumes for drug production," Dr Balan said.
He explained there will be further research to investigate its effectiveness on different cancers, potentially leading to extensive drug development.
Ref : http://pubs.rsc.org/en/content/articlelanding/2012/ob/c2ob26649k#!divAbstract
Subscribe to:
Posts (Atom)